Objective To investigate the clinical value of active anti-osteoporosis treatment for the prevention or improvement of lumbar disc herniation in patients with osteoporosis.Methods From May 2011 to July 2013,300 patients of osteoporosis were collected,of whom 171 cases not merged lumbar disc herniation,according to the different treatment,the patients were divided into:A1 group(41 cases),A2 group (38 cases),A3 group (39 cases) and control group (53 cases);129 cases with intervertebral disc herniation were divided into B1 group (33 cases),group B2 (29 cases),B3 group (36 cases),as well as the control group B (31 cases).Group A1 and B1 were given:alfacalcidol soft capsules and oral calcium agent+alendronate sodium tablets of standardized treatment of osteoporosis;A2 group and B2 group were given alfacalcidol soft capsules and oral calcium agent + ribavirin to the standardized treatment of phosphonic acid intravenous injection;A3 group and B3 group were only given ossification alcohol glue pill + oral calcium based treatment.Control group A,B group were refused to accept the above treatment.Results All patients were treated for 2 years,improvements in bone mineral density,A1,A2,B1,B2 group ＞A3 and B3 group＞control group A and B;rate of occurrence in lumbar disc herniation A1,A2 ＜A3 group ＜control group A;in the improvement of lumbar protrusion of the intervertebral disc,B1,B2 group ＞B3 group ＞ of B group.All the above differences were statistically significant (P ＜0.05).Conclusion Patients with osteoporosis regardless of whether or not accompanied by lumbar disc herniation,shall be given a positive anti-osteoporosis treatment,whether for the prevention of lumbar protrusion of the intervertebral disc,or to improve the symptoms,have a good effect.%目的 对于骨质疏松症患者,探讨积极的抗骨质疏松治疗对于预防或改善腰椎间盘突出症的临床价值.方法 2011-05-2013-07收治300例骨质疏松症患者,其中不合并腰椎间盘突出症者171例,依据治疗方案的不同,分为:A1组41例,A2组38例,A3组39例,以及对照组A 53例;合并椎间盘突出者129例,分为B1组33例,B2组29例,B3组36例,以及对照组B31例.A1和B1组,均给予:阿法骨化醇胶丸+口服钙剂+阿伦磷酸钠片的规范化抗骨质疏松治疗;A2和B2组给予:阿法骨化醇胶丸+口服钙剂+唑来膦酸静脉注射的规范化治疗;A3和B3组仅给予:阿法骨化醇胶丸+口服钙剂的基础治疗.对照组A、B组均拒绝接受上述治疗.结果 所有患者治疗2年后,在骨密度改善方面,A1、A2组、B1、B2组＞A3和B3组＞对照组A和B;在腰椎间盘突出症的发生率方面,A1、A2组＜A3组＜对照组A;在腰椎间盘突出症的改善方面,B1、B2组＞B3组＞对照组B.上述差异均有统计学意义(P＜0.05).结论 骨质疏松症患者无论是否伴有腰椎间盘突出症,均应给予积极的抗骨质疏松治疗,无论对于预防腰椎间盘突出症的发生,还是改善其症状,均有良好的作用.
展开▼
